CWM LLC has more than doubled its stake in Regeneron Pharmaceuticals, snapping up an additional 2,007 shares to now hold a ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Eylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.

The pharmaceutical company said it remained confident in the benefit and risk profile of Blenrep and will continue to work ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

New York State Common Retirement Fund trimmed its Regeneron stake by 5% in Q1, selling over 6,800 shares worth millions.

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

Stay with Moneycontrol to get real time updates on US MARKET share price, top gainers, top losers and market insights.

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

Analysts expect the S&P 500 to rise 7.5% over the next year, according to a recent analysis of stock price targets. Wall ...